Safety and Efficacy Study of IMSA101 in Refractory Malignancies

Solid Tumor, Adult Clinical Trial

Official title:

Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04020185
• Other study ID #: IMSA101-101
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: September 23, 2019
• Est. completion date: September 15, 2023

Study information

• Verified date: October 2023
• Source: ImmuneSensor Therapeutics Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Open-label, dose escalation (Phase I) and dose expansion (Phase IIA) study of patients receiving intra-tumoral IMSA101 alone or in combination with an immune checkpoint inhibitor (ICI) (Phase I and II)

Description:

This is an open-label, dose escalation (Phase I), and dose expansion (Phase IIA) study designed to evaluate safety and efficacy of IMSA101 alone or in combination with an ICI (Phase I and II). Therefore, the study will be conducted in 2 phases. The dose of IMSA101 in Phase IIA will be based on the monotherapy and combination Recommended Phase 2 Doses (RP2Ds) from Phase I.

The following methodology applies to all patients (unless otherwise indicated):

• Pre-treatment screening radiographic tumor assessments will be collected within 30 days prior to initial dose for all patients. Photographic assessments for cutaneously-accessible lesions will be performed as detailed in a separate photography manual.

• Treatment cycles will be 28 days in duration with lesions injected weekly on Day 1 for the first three weeks of Cycle 1 and then every 2 weeks during cycles 2 and beyond.

• A single pre-defined lesion/lesion site (longest diameter ≥ 10 mm and ≤ 35 mm) shall be injected throughout study duration, if possible. Where the original injection site is considered by the investigator to become inaccessible, a second lesion/lesion site shall be selected as a replacement and this shall be used henceforth so long as it is considered accessible. Subsequent injection sites shall be replaced when they are considered inaccessible.

• Where no remaining accessible lesions are present and where benefit of IMSA101 therapy is, in the opinion of the investigator, being derived by the patient, continued injections of IMSA101 into the vicinity of an inaccessible lesion or, in the case that a lesion can no longer be radiographically visualized, into the last known location of the non-visible lesion shall be allowed.

• Patients will be admitted to the hospital for observation overnight following IT injection with IMSA101 on Day 1 of Cycle 1. Patients will be followed throughout the study for drug tolerability and safety by collection of clinical and laboratory data, including information on adverse events (AEs) using CTCAE v5.0 criteria, serious adverse events (SAEs), DLTs, concomitant medications, vital signs, and electrocardiograms (ECGs).

• Patients will be assessed for anti-tumor efficacy based on radiographic assessments and if applicable, photographic tumor assessments, and analysis of Objective Response Rate (ORR), Time to Progression (TTP), and Progression Free Survival (PFS) using RECIST criteria (Appendix 13.2) at screening and the end (≤ 7 days) of even numbered cycles (Cycle 2, Cycle 4, etc.) after the first dosing.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: September 15, 2023
• Est. primary completion date: September 15, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent and mental capability to understand the informed consent

2. Male or female patients > 18 years of age

3. Histologically or cytologically documented locally advanced or metastatic solid tumor malignancies refractory to or otherwise ineligible for treatment with standard-of-care agents/regimens, including but not limited to:

• Malignant melanoma

• Hormone receptor negative breast cancer

• Gastro-esophageal cancer

• Non-small cell lung cancer

• Head and neck cancer

• Hepatoma

• Renal cell carcinoma

4. Eastern Cooperative Oncology Group (ECOG) performance status of = 1

5. Evaluable or measurable disease as follows:

• A minimum of 3 RECIST-evaluable lesions: one that is suitable for injection and biopsied; one non-injected that will be biopsied for abscopal effect; and one measurable lesion that will be followed for response only.

• Injectable tumors shall be accessed by intralesional (cutaneous) or percutaneous injection only, including those lesions that are visible, palpable, or detectable by standard radiographic or ultrasound methods. Neither surgical procedures nor endoscopically-guided injections including those to endobronchial, endoluminal, or endosinusial spaces shall be allowed. While no anatomic locations are required or disallowed, lesions selected for intratumoral injection must, in the opinion of the investigator:

• Not be immediately adjacent to blood vasculature or other physiologic landmarks in such a way that will accrue undue safety risk to the patient

• Have longest diameter = 10 mm and = 50 mm

• Be fully efficacy evaluable per RECIST v1.1 criteria

6. Life expectancy > 3 months (Phase I) and > 6 months (Phase IIA)

7. ECG without evidence of clinically meaningful conduction abnormalities or active ischemia as determined by the investigator

8. Acceptable organ and marrow function as defined below:

• Absolute neutrophil count > 1,500 cells/µL

• Platelets > 50,000 cells/µL

• Total bilirubin = 1.5 times the upper limit of normal (ULN)

• Aspartate aminotransferase (AST)/alanine transaminase (ALT) = 2.5 times ULN. If liver metastases are present, AST/ALT < 5 times ULN

• Serum creatinine < 1.5 mg/dL and a measured creatinine clearance = 50 mL/min using the Cockcroft-Gault formula

• Prothrombin time (PT)/partial thromboplastin time (PTT) = 1.5 times ULN

9. Women of child-bearing potential (defined as a female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea for at least 12 consecutive months with an appropriate clinical profile at the appropriate age, e.g., greater than 45 years) must have a negative serum pregnancy test prior to first dose of study drug

10. Male and female patients with reproductive potential must agree to use two forms of highly effective contraception throughout the study

11. Phase I combination only: Demonstrated RECIST stable disease through = 4 consecutive cycles of an approved PD-1 or PD-L1 targeted ICI with no Grade = 3 CTCAE events considered by the investigator to be drug-related.

Exclusion Criteria:

1. Anti-cancer therapy within 4 weeks or < 5 half-lives of the first dose of study drug.

2. Failure to recover to Grade 1 or less from clinically significant AEs due to prior anti-cancer therapy.

3. Known untreated brain metastases or treated brain metastases that have not been stable (scan showing no worsening of central nervous system (CNS) lesion[s] and no requirement of corticosteroids) = 4 weeks prior to study enrollment

4. Baseline prolongation of QT/QTc interval (QTc interval > 470)

5. Uncontrolled intercurrent illness (including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations) that in opinion of the investigator would limit compliance with study requirements

6. Women who are pregnant or breastfeeding

7. Phase I combination only: Prior tumor progression through PD-1 or PD-L1 targeted ICI therapy.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor, Adult

Intervention

Drug:
• IMSA101
IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.
• Immune checkpoint inhibitor (ICI)
Administered according to product label
• Immuno-oncology (IO) therapy
Administered according to product label

Locations

Country	Name	City	State
United States	Northwestern University	Chicago	Illinois
United States	UT Southwestern	Dallas	Texas
United States	MD Anderson Cancer Center	Houston	Texas
United States	UC San Diego Moores Cancer Center	La Jolla	California
United States	Atlantic Health System/Morristown Medical Center	Morristown	New Jersey
United States	Honor Health	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
ImmuneSensor Therapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose	Number of adverse events and dose limiting toxicities per CTCAE v 5.0	2 years
Secondary	Pharmacokinetic Sampling (Ph I)	Area under the curve minimum plasma concentration	2 years
Secondary	Pharmacokinetic Sampling (Ph I)	Maximum plasma concentration	2 years
Secondary	Pharmacokinetic Sampling (Ph I)	Elimination half life	2 years
Secondary	Anti-tumor Effects	Tumor response, based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1), in patients evaluable for response.	4 years
Secondary	Anti-tumor Effects	Duration of response (DOR), based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1), in patients evaluable for response.	4 years
Secondary	Anti-tumor Effects	Time to tumor progression (TTP), based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1), in patients evaluable for response.	4 years
Secondary	Anti-tumor Effects	Progression free survival (PFS), based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1), in patients evaluable for response.	4 years